Meet our investors

What follows in this document is a selection of 350 equity and strategic investors that have active mandates in investing and supporting biotech, medtech and healthtech companies from across drug discovery and invention, to on-the-market and diffusion, and everyone in-between.

For the purpose of this report, we’ve aggregated and summarised the investment preferences of these firms and highlighted which therapeutic and technology areas are attracting their attention right now.